News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Invivyd reported LIBERTY Phase 3: VYD2311 showed superior safety/tolerability vs mRNA vaccine and will use data for an accelerated BLA submission.
  • BeyondSpring received FDA Fast Track for plinabulin plus docetaxel in post-ICI non-squamous NSCLC and sold Chinese subsidiary stake to fund Phase 3 enrollment.
  • Immix Biopharma priced $125M equity offering to advance its CAR-T NXC-201 program and support general corporate purposes.
  • uniQure posted 36–48 month data showing sustained slowing of Huntington's progression, supporting its recent BLA submission.
  • Unicycive resubmitted NDA for oxylanthanum carbonate with new CMC and stability data, expecting FDA acceptance within 30 days.
  • Polar Power won a 50-unit trial order from a major Southeast Asian telecom, with potential five-year program worth about $60 million.

Latest Articles

California Water Service Group Schedules 2026 Second-Quarter Earnings Results Announcement and Conference Call

California Water Service Group Schedules 2026 Second-Quarter Earnings Results Announcement and Conference Call

California Water Service Group (NYSE: CWT) will release its 2026 second-quarter earnings results on July 30, 2026, followed by a conference call hosted by its CEO and CFO. The company serves over 2.2 million people across five states through its regulated water utilities. Investors are invited to participate via phone or webcast, with a replay avai…

Ooma Chief Legal Officer Yeh Executes Stock Sale Amid Strong Fiscal Year

Ooma Chief Legal Officer Yeh Executes Stock Sale Amid Strong Fiscal Year

Jenny C. Yeh, Senior Vice President and Chief Legal Officer at Ooma Inc., executed a sale of company stock totaling approximately $49,687. The transaction occurred on July 7, 2026, as Ooma's shares trade near their 52-week high. This executive sale follows Ooma's strong start to fiscal 2027, with the company delivering earnings per share and revenu…

Whitestone REIT Shareholders Approve Acquisition by Ares

Whitestone REIT Shareholders Approve Acquisition by Ares

Whitestone REIT's shareholders have approved the all-cash acquisition by Ares Real Estate funds for $19.00 per share, valuing the transaction at approximately $1.7 billion. The deal follows a definitive merger agreement signed in April 2026 and is expected to close around July 14, 2026, subject to customary closing conditions.

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Corporation announced preliminary unaudited sales results for Q2 and the first six months of 2026, showing 11.5% and 20.9% increases respectively compared to 2025. Growth was primarily driven by a 27.7% domestic sales increase, despite a decline in international sales. The company attributed the growth to strong product availability, a foc…

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics announced a strategic R&D collaboration with PegBio to explore oral delivery of PegBio's novel obesity and metabolic disease molecules using Rani's proprietary RaniPill® platform. This partnership aims to broaden Rani's obesity treatment pipeline by advancing multiple new candidates with differentiated mechanisms of action into cl…

Amneal to Report Second Quarter 2026 Results on July 30, 2026

Amneal to Report Second Quarter 2026 Results on July 30, 2026

Amneal Pharmaceuticals, a diversified global biopharmaceutical company, announced that it will report its second quarter 2026 financial results on July 30, 2026, before the market opens. The company will host a live audio webcast for investors and interested parties to discuss the financial results and operational updates.

Varonis Announces Date of Second Quarter 2026 Financial Results

Varonis Announces Date of Second Quarter 2026 Financial Results

Varonis Systems, a leader in data and AI security, announced the date for its second quarter 2026 financial results release. The company will report results after US market close on July 28, 2026, and hold a conference call to discuss the financial outcomes. The event will be accessible via phone and webcast, with a replay available for one year.